CagriSema and MariTide are both weight-loss injectables working their way toward the market, but they’re at different stages and use different designs. CagriSema, a weekly injection combining two hormones, produced about 22% weight loss in trials and is further along, sitting under FDA review. MariTide offers once-monthly dosing with roughly 20% weight loss and remains in phase 3 testing. Neither is approved or available to prescribe yet. Here’s how they compare and what you can use in the meantime.<\/p>\n
CagriSema pairs two medications in one injection: cagrilintide, an amylin analog, and semaglutide, the familiar GLP-1 drug behind Wegovy. Amylin and GLP-1 curb appetite through different pathways, and combining them appears to add up to more weight loss than semaglutide alone. It’s given as a weekly shot.<\/p>\n
MariTide works through the GLP-1 receptor while blocking the GIP receptor, and it’s engineered as a long-acting molecule that lingers in the body for weeks. That’s what enables once-monthly dosing, a standout feature in a field where nearly everything else is weekly.<\/p>\n
CagriSema’s trial results have been strong. In the REDEFINE 1 trial<\/a> published in the New England Journal of Medicine in 2025, CagriSema produced about 22.7% average weight loss in adults with obesity. MariTide’s phase 2 data showed up to roughly 20% weight loss at 52 weeks, with no plateau observed by the study’s end.<\/p>\n CagriSema is meaningfully ahead. Its manufacturer has filed for FDA approval, and a decision is anticipated in late 2026, so it could reach patients before MariTide does. MariTide is still running its phase 3 MARITIME program, with key results expected in 2027 and any approval coming later.<\/p>\n So the comparison is partly about timing and partly about preference. CagriSema currently shows somewhat higher weight loss and is nearer to launch, while MariTide’s appeal is the convenience of a monthly shot. Both remain out of reach for now, which is the most important practical point.<\/p>\n Consider a hypothetical patient weighing whether to wait for one of these. Since CagriSema is under review and MariTide is further back, “waiting” could mean months to years without treatment. Starting an available option now, then reassessing when these launch, is usually the more sensible path. TrimRx prescribes injectable semaglutide and tirzepatide in compounded and brand-name forms, and you can see what suits you on the TrimRx homepage<\/a> or by taking the quiz<\/a>.<\/p>\n CagriSema showed slightly higher weight loss in trials (about 22.7% versus up to 20% for MariTide), but MariTide offers monthly rather than weekly dosing. Neither is available yet, so real-world comparisons are not possible.<\/p>\n CagriSema is under FDA review with a decision expected in late 2026. MariTide is earlier, with phase 3 results expected in 2027 and any approval following after that.<\/p>\n No. CagriSema is not yet approved, and MariTide is investigational. For effective options you can start today, injectable semaglutide and tirzepatide are available through providers like TrimRx.<\/p>\n\n\n
\n \nFeature<\/th>\n CagriSema<\/th>\n MariTide<\/th>\n<\/tr>\n<\/thead>\n \n Mechanism<\/td>\n Amylin analog plus GLP-1 (cagrilintide + semaglutide)<\/td>\n GLP-1 agonist plus GIP antagonist<\/td>\n<\/tr>\n \n Dosing<\/td>\n Weekly injection<\/td>\n Monthly injection<\/td>\n<\/tr>\n \n Weight loss in trials<\/td>\n ~22.7%<\/td>\n Up to ~20% (no plateau seen)<\/td>\n<\/tr>\n \n Development stage<\/td>\n Under FDA review<\/td>\n Phase 3 enrolling<\/td>\n<\/tr>\n \n Availability<\/td>\n Not yet available<\/td>\n Not available (investigational)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Which Is Closer to Reality<\/h3>\n
Frequently Asked Questions<\/h3>\n
Is CagriSema or MariTide more effective?<\/h4>\n
When will CagriSema and MariTide be available?<\/h4>\n
Can I take either drug now?<\/h4>\n